Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) EBITDA: 2023-2024

Historic EBITDA for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to -$42.3 million.

  • Contineum Therapeutics' EBITDA fell 98.82% to -$15.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$42.3 million, marking a year-over-year decrease of 284.66%. This contributed to the annual value of -$42.3 million for FY2024, which is 284.66% down from last year.
  • Contineum Therapeutics' EBITDA amounted to -$42.3 million in FY2024, which was down 284.66% from $22.9 million recorded in FY2023.
  • In the past 5 years, Contineum Therapeutics' EBITDA ranged from a high of $22.9 million in FY2023 and a low of -$42.3 million during FY2024.
  • Over the past 2 years, Contineum Therapeutics' median EBITDA value was -$9.7 million (recorded in 2023), while the average stood at -$9.7 million.
  • Data for Contineum Therapeutics' EBITDA shows a maximum YoY plummeted of 284.66% (in 2024) over the last 5 years.
  • Over the past 2 years, Contineum Therapeutics' EBITDA (Yearly) stood at $22.9 million in 2023, then tumbled by 284.66% to -$42.3 million in 2024.